bioRxiv Science⌕ Search

Biology subjects

Haas, P.-J. A.

Publications and source records attributed to Haas, P.-J. A..

2 recordsLinked to original sources

Anti-phage defence systems are enriched in multidrug-resistant Pseudomonas aeruginosa

Pseudomonas aeruginosa encodes diverse defence systems against phages and mobile genetic elements, yet their variation across clinical contexts remains unclear. Here, we present a large-scale comparative analysis of the P. aeruginosa defensome across both public and clinically highly relevant datasets, including from patients with chronic lung disease and multidrug-resistant isolates. Our analysis shows that while influences on defensome composition are minor, multidrug-resistant isolates encode more defence systems and cystic fibrosis-associated isolates have fewer. Across phylogenetic clusters, defensome size correlates with cluster abundance, suggesting that defence-rich lineages persist more successfully across environments. Lastly, comparative analysis with other Pseudomonas species reveals enrichment of anti-plasmid systems in P. aeruginosa. Overall, these findings have important implications for phage therapy: multidrug-resistant infections may be more difficult to treat, while cystic-fibrosis-associated isolates may have higher phage susceptibility. This work provides a framework for understanding defensome variation and guiding the decision-making process of phage-based therapies.

microbiology↗

Bacterial immune evasion proteins: The therapeutic potential of CHIPS

Bacterial pathogens have evolved to secrete strong anti-inflammatory proteins that target the immune system. It was long speculated whether these virulence factors could serve as therapeutics in diseases in which abnormal immune activation plays a role. We adopted the secreted Chemotaxis Inhibitory Protein of Staphylococcus aureus (CHIPS) as a model virulence factor-based therapeutic agent for diseases in which C5aR1 stimulation plays an important role. We show that administration of CHIPS in human C5aR1 knock-in mice successfully dampens C5a mediated neutrophil migration during immune complex-initiated inflammation. Subsequent CHIPS toxicology studies in animal models were promising. However, during a small phase-I trial, healthy human volunteers showed adverse effects directly after CHIPS administration. Subjects showed clinical signs of anaphylaxis with mild leukocytopenia and increased C-reactive protein concentrations, suggesting an inflammatory response, which are believed to be related to the presence of relatively high circulating anti-CHIPS antibodies. Even though our data in mice shows CHIPS as a potential anti-inflammatory agent, safety issues in human subjects temper the use of CHIPS in its current form as a therapeutic candidate. The use of staphylococcal proteins, or other bacterial proteins, as therapeutics or immune-modulators in humans is severely hampered by pre-existing circulating antibodies.

microbiology↗